Table 4.
Association between the use of sulfonylurea and the risk of site-specific cancer.
| Sulfonylureas (54513.5 person-years) | Metformin (40082.1 person-years) | HR (95% CI) | |||
|---|---|---|---|---|---|
| Cases | Incidence (/100,000 person years) | Cases | Incidence /100,000 person years) | ||
| Gastric cancer | 72 | 132 | 45 | 112 | 0.98 (0.67–1.43) |
| Colorectal cancer | 45 | 83 | 26 | 65 | 1.09 (0.67–1.77) |
| Liver cancer | 26 | 48 | 24 | 60 | 0.78 (0.43–1.41) |
| Pancreas cancer | 18 | 33 | 16 | 40 | 0.94 (0.46–1.96) |
| Lung cancer | 94 | 172 | 50 | 125 | 1.19 (0.82–1.71) |
| Breast cancer | 27 | 50 | 19 | 47 | 0.89 (0.46–1.73) |
| Prostate cancer | 26 | 48 | 16 | 40 | 0.87 (0.46–1.68) |
| Bladder cancer | 15 | 28 | 9 | 22 | 1.68 (0.64–4.40) |
| Thyroid cancer | 25 | 46 | 22 | 55 | 0.82 (0.45-1.50) |
| Lymphoma & leukemia | 29 | 53 | 11 | 27 | 2.23 (1.04–4.76) |
| All other cancers | 85 | 156 | 53 | 132 | 1.26 (0.86–1.82) |